This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.
Dr. Aadel Chaudhuri of Washington University will share details of the study, which applied Avenio targeted next-generation sequencing (NGS) *to plasma, tumor and urine samples acquired on the day of curative-intent surgery from prospectively enrolled oligometastatic CRC patients.
The study demonstrated that tumor-naïve plasma ctDNA analysis can sensitively and specifically detect MRD in patients with oligometastatic CRC after neoadjuvant chemotherapy, while urine-based ctDNA MRD detection is less sensitive than plasma. Dr. Chaudhuri will discuss these findings in detail.
* For Research Use Only. Not for use in diagnostic procedures.
